Actively Recruiting
Phase 1a1b Randomized, Placebo-Controlled Study Evaluating ARQ-234 in Healthy Volunteers and Adults With Moderate to Severe Atopic Dermatitis
Led by Arcutis Biotherapeutics, Inc. · Updated on 2026-10-23
125
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ARQ-234, a subcutaneous injectable solution, in a first-in-human, Phase 1, double-blind, randomized, placebo-controlled study. The study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ-234 in both healthy volunteers and participants with moderate to severe atopic dermatitis AD. The research includes multiple parts with staggered starts to understand effects in different participant groups. The study consists of three parts Part A involves single ascending dose SAD cohorts with healthy volunteers and AD participants Part B includes multiple ascending dose MAD cohorts with AD participants and Part C is a proof-of-concept expansion in AD participants. Participants receive ARQ-234 or placebo via subcutaneous injection, with dosing and escalation schedules varying by cohort. Each part evaluates increasing doses to study safety and drug behavior. Participants will be involved in screening, dosing, and follow-up visits lasting up to 16 weeks for Part A and up to 30 weeks for Parts B and C. Assessments include adverse event monitoring, disease severity scoring using the Eczema Area and Severity Index EASI, body surface area affected, itch severity, SCORAD, POEM, and Investigators Global Assessment scores. Blood samples will be collected to study drug concentrations. Safety evaluations, questionnaires, and clinical exams will monitor participants throughout the study.
CONDITIONS
Brief Title
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Research Team
A
Arcutis Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here